会员体验
专利管家（专利管理）
工作空间（专利管理）
风险监控（情报监控）
数据分析（专利分析）
侵权分析（诉讼无效）
联系我们
交流群
官方交流：
QQ群： 891211   
微信请扫码    >>>
现在联系顾问~
下载
著录项
PDF全文
热词
    • 1. 发明申请
      WO2010092342A1 ORGANOSILICON COMPOUNDS AND THEIR USE AS THE MODULATORS OF THE TRPV1 RECEPTOR 审中-公开
    • ORGANOSILICON COMPOUNDS AND THEIR USE AS THE MODULATORS OF THE TRPV1 RECEPTOR
    • 有机硅化合物及其作为TRPV1受体调节剂的用途
    • WO2010092342A1
    • 2010-08-19
    • PCT/GB2010/000246
    • 2010-02-10
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED , AYSCOUGH, Andrew Paul , SHOWELL, Graham Andrew , TEALL, Martin Richard , TEMPLE, Hannah Elizabeth , AHMED, Saleh
    • AYSCOUGH, Andrew Paul , SHOWELL, Graham Andrew , TEALL, Martin Richard , TEMPLE, Hannah Elizabeth , AHMED, Saleh
    • C07F7/08 , A61K31/695
    • C07F7/0814
    • A compound having the Formula (1): wherein: X 1 , X 2 , X 3 and X 4 independently represent CH or N; R 1 , R 2 and R 3 independently represent C 1-6 alkyl, C 3-8 cycloalkyl or C 3-8 cycloalky IC 1-6 alkyl, each of which groups may be optionally substituted with one or more substituents independently selected from halogen and haloC 1-6 alkyl; R 4 , R 5 , R 6 , R 7 , R 8 and R 9 independently represent H, C 1-6 alkyl, C 3-8 cycloalkyl or -Q I -OR 14 , or R 4 and R 9 may join to form a bridging C 1-6 alkylene chain; R 10 represents aryl or heteroaryl, each of which may be optionally substituted by one or more substituents, independently selected from halogen, C 1-6 alkyl, haloC 1-6 alkyl, hydroxyC 1-6 alkyl, haloC 1-6 alkoxy, cyano, -Q 2 -CO 2 R 12 , -Q 2 -COR 12 , -Q 2 -CONR 12 R 13 , -Q 2 -OR 12 , -Q 2 -NR 12 Rn, -Q 2 -NR 12 SO 2 R 13 , -Q 2 - NR 12 COR 13 , -Q 2 -SO 2 NR 12 R 13 , -Q 2 -S(O) m R 12 , -Y-aryl, -Y-heteroaryl, -Y-C 3-8 cycloalkyl and -Y-heterocyclyl; Q 1 and Q 2 independently represent a covalent bond, C 1-6 alkylene, or 1-6 alkylene substituted with hydroxy; R 12 and R 13 independently represent a H atom, or a C 1-6 alkyl or C 3-8 cycloalkyl group, in which each group may be optionally substituted with one or more C 1-6 alkoxy; or when R 12 and R 13 are attached to the same nitrogen atom they may join to form a nitrogen containing heterocyclyl ring, which may be optionally substituted with one or more substituents independently selected from C 1-6 alkyl and C 1-6 alkoxy; R 14 represents a H atom, or a C 1-6 alkyl or C 3-8 cycloalkyl group, in which each group may be optionally substituted with one or more C 1-6 alkoxy; Y represents a covalent bond, C 1-6 alkylene, or -O-. m represents 0, 1 or 2; R 11 , which is optionally present and may be attached to any available carbon atom X 1 to X 4 instead of H, represents halogen, haloC 1-6 alkyl, C 1-6 alkoxy, haloC 1-6 alkoxy, cyano or C 1-6 alkyl which may be optionally substituted with one or more substituents independently selected from halogen, haloC1-6 alkyl and OR 16 ; q represents 0, 1 or 2; W represents -(CH 2 ) n -, which may be optionally substituted with one or more substituents independently selected from C 1-6 alkyl, C 3-8 cycloalkyl and -Q 3 -OR 15 ; n represents 1 or 2; Q 3 represents a covalent bond or C1-6 alkylene; R 15 represents H, C 1-6 alkyl, or C 3-8 cycloalkyl; R 16 is as defined for R 14 ; or a pharmaceutically acceptable salt or ester thereof. Uses of the compounds as modulators of the TrpVl receptor are also disclosed.
    • 具有式（1）的化合物：其中：X 1，X 2，X 3和X 4独立地表示CH或N; R 1，R 2和R 3独立地表示C 1-6烷基，C 3-8环烷基或C 3-8环烷基IC 1-6烷基，其各自可以任选地被一个或多个独立地选自卤素和卤代C 1-6烷基的取代基取代; R 4，R 5，R 6，R 7，R 8和R 9独立地表示H，C 1-6烷基，C 3-8环烷基或-QI-OR 14，或者R 4和R 9可以连接形成桥连C 1-6亚烷基链; R 10表示芳基或杂芳基，其各自可以任选被一个或多个独立地选自卤素，C 1-6烷基，卤代C 1-6烷基，羟基C 1-6烷基，卤代C 1-6烷氧基，氰基，-Q 2 -CO 2 R 12， -Q2-COR12，-Q2-CONR12R13，-Q2-OR12，-Q2-NR12Rn，-Q2-NR12SO2R13，-Q2- NR12COR13，-Q2-SO2NR12R13，-Q2-S（O）mR12，-Y-芳基， Y-杂芳基，-Y-C 3-8环烷基和-Y-杂环基; Q1和Q2独立地表示共价键，C1-6亚烷基或被羟基取代的1-6个亚烷基; R 12和R 13独立地表示H原子或C 1-6烷基或C 3-8环烷基，其中每个基团可以任选被一个或多个C 1-6烷氧基取代; 或当R 12和R 13连接到相同的氮原子上时，它们可以连接形成含氮杂环基环，其可任选地被一个或多个独立地选自C 1-6烷基和C 1-6烷氧基的取代基取代; R 14表示H原子或C 1-6烷基或C 3-8环烷基，其中各基团可任选被一个或多个C 1-6烷氧基取代; Y表示共价键，C 1-6亚烷基或-O-。 m表示0,1或2; 任选存在并且可以连接到任何可用的碳原子X 1至X 4而不是H的R 11表示卤素，卤代C 1-6烷基，C 1-6烷氧基，卤代C 1-6烷氧基，氰基或C 1-6烷基，其可任选被一个 或更多取代基，其独立地选自卤素，卤代C 1-6烷基和OR 16; q表示0,1或2; W表示 - （CH 2）n - ，其可任选被一个或多个独立地选自C 1-6烷基，C 3-8环烷基和-Q 3 -OR 15的取代基取代; n表示1或2; Q3表示共价键或C 1-6亚烷基; R 15表示H，C 1-6烷基或C 3-8环烷基; R16如R14所定义; 或其药学上可接受的盐或酯。 还公开了化合物作为TrpV1受体的调节剂的用途。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
    • 2. 发明申请
      WO1995011880A1 SUBSTITUTED AMIDES AS TACHYKININ ANTAGONISTS 审中-公开
    • SUBSTITUTED AMIDES AS TACHYKININ ANTAGONISTS
    • 作为TACHYKININ ANTAGONISTS的替代药物
    • WO1995011880A1
    • 1995-05-04
    • PCT/GB1994002342
    • 1994-10-24
    • MERCK SHARP & DOHME LIMITED , CHAMBERS, Mark, Stuart , HARRISON, Timothy , OWENS, Andrew, Pate , TEALL, Martin, Richard , WILLIAMS, Brian, John
    • MERCK SHARP & DOHME LIMITED
    • C07C233/29
    • C07D233/64 , C07C233/11 , C07C233/13 , C07C233/22 , C07C235/34 , C07C235/46
    • A class of substituted amide compounds of formula (I), are antagonists of tachykinins, especially substance P, and are therefore of use in the treatment or prevention of physiological disorders associated with an excess of tachykinins, such as inflammation, pain, migraine and emesis. In formula (I) Ar and Ar each independently represents a phenyl group optionally substituted by one, two or three groups selected from halo, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C3-6cycloalkylC1-4alkyl, trifluoromethyl, cyano, nitro, SR , SOR , SO2R , OR , NR R , NR COR , NR CO2R , CO2R or CONR R , wherein R and R are each independently H, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C3-6cycloalkylC1-4alkyl, phenyl or trifluoromethyl; Q represents Ar or a group of formula Het-(CH2)n-, where n is 1 or 2 and Het is a five or six membered nitrogen containing heterocyclic group with 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulphur with at most one oxygen or sulphur atom, which group may have the residue of a further 5 or 6 membered aromatic ring fused thereto, and which group may be optionally substituted by a group selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, oxo, thioxo, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR , SR , SOR , SO2R , NR R , NR COR , NR CO2R , CO2R , CONR R or phenyl optionally substituted by 1, 2 or 3 groups selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, OR , SR , SOR , SO2R , NR R , NR COR , CO2R , or CONR R , where R and R are each independently H, C1-6alkyl, trifluoromethyl or phenyl; X represents a -CO-NR- or -NR-CO- group, where R is hydrogen, C1-6alkyl, or methyl substituted by a C2-6alkenyl or C2-6alkynyl group; one of Y and Y is a bond or C1-4alkylene group and the other is a C1-4alkylene group; with the proviso that when Ar and Q are dimethoxyphenyl, -Y -X-Y -Ar is not -CH2CON(CH3)CH2C6H5.
    • 一类取代的式（I）酰胺化合物是速激肽，特别是物质P的拮抗剂，因此可用于治疗或预防与超速激肽相关的生理紊乱症，例如炎症，疼痛，偏头痛和呕吐 。 在式（I）中，Ar 1和Ar 2各自独立地表示任选被一个，两个或三个选自卤素，C 1-6烷基，C 2-6烯基，C 2-6炔基，C 3-6环烷基，C 3 -6环烷基C 1-4烷基，三氟甲基，氰基，硝基，SR a，SOR a，SO 2 R a，OR a，NR a R b，NR a COR b，NR 其中R a和R b各自独立地为H，C 1-6烷基，C 2-6烯基，C 2-6炔基，C 3 -C 10环烷基 C 3-6环烷基C 1-4烷基，苯基或三氟甲基; Q表示Ar 1或式Het-（CH 2）n - 的基团，其中n为1或2，Het为含有1,2或3个选自氮，氧或氧的杂原子的5或6元含氮杂环基 具有至多一个氧或硫原子的硫，该基团可以具有与其稠合的另外5或6元芳环的残基，该基团可以任选地被选自C 1-6烷基，C 2-6烯基， 6-炔基，C3-7环烷基，C3-7环烷基C 1-4烷基，氧代，硫代，卤素，氰基，硝基，三氟甲基，三甲基甲硅烷基，OR c，SR c，SOR c，SO 2 R c，NR c， R d，NR c，C d，NR c CO 2 R d，CO 2 R c，CONR c R d或任选被1,2或3个选自C 1的基团取代的苯基 C 1-6烷基，C 2-6烯基，C 2-6炔基，C 3-7环烷基，C 3-7环烷基C 1-4烷基，卤素，氰基，硝基，三氟甲基，三甲基甲硅烷基，OR c， NR c，R c，R c，R d，CO 2 R c或CONR c R d，其中R c和R d各自独立地为H，Cl -6-烷基，三氟甲基 或苯基; X表示-CO-NR-或-NR-CO-基，其中R是氢，C 1-6烷基或被C 2-6烯基或C 2-6炔基取代的甲基; Y 1和Y 2之一是键或C 1-4亚烷基，另一个是C 1-4亚烷基; 条件是当Ar 1和Q是二甲氧基苯基时，-Y 1 -X-Y 2 -Ar 2不是-CH 2 CON（CH 3）CH 2 C 6 H 5。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
    • 7. 发明申请
      WO1995018124A1 SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS 审中-公开
    • SUBSTITUTED MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
    • 取代的吗啉衍生物及其作为治疗剂的用途
    • WO1995018124A1
    • 1995-07-06
    • PCT/GB1994002819
    • 1994-12-23
    • MERCK SHARP & DOHME LIMITED , BAKER, Raymond , HARRISON, Timothy , MACLEOD, Angus, Murray , OWENS, Andrew, Pate , SEWARD, Eileen, Mary , SWAIN, Christopher, John , TEALL, Martin, Richard
    • MERCK SHARP & DOHME LIMITED
    • C07D413/06
    • C07D413/06 , C07D413/14 , C07F9/6533 , C07F9/65583
    • The present invention relates to compounds of formula (I), wherein R is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, CF3, NO2, CN, SR , SOR , SO2R , CO2R , CONR R , C2-6 alkenyl, C2-6 alkynyl or C1-4 alkyl substituted by C1-4 alkoxy, where R and R are hydrogen or C1-4 alkyl; R is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy substituted by C1-4 alkoxy or CF3; R is hydrogen, halogen or CF3; R is selected from the definitions of R ; R is selected from the definitions of R ; R is a 5-membered or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O, =S or a C1-4 alkyl group, and optionally substituted by an aminoalkyl group; R and R are hydrogen or C1-4 alkyl, or R and R are joined to form a C5-7 ring; X is C1-4 alkylene optionally substituted by oxo; and Y is a C1-4 alkyl group optionally substituted by hydroxyl; with the proviso that if Y is C1-4 alkyl, R is substituted at least by an aminoalkyl group; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment of pain, inflammation, migraine and emesis.
    • 本发明涉及式（I）化合物，其中R 1是氢，卤素，C 1-6烷基，C 1-6烷氧基，CF 3，NO 2，CN，SR a，SOR a，SO 2 R， α，CO 2 R a，CONR a R b，C 2-6烯基，C 2-6炔基或被C 1-4烷氧基取代的C 1-4烷基，其中R a和R b是氢 或C 1-4烷基; R 2是氢，卤素，C 1-6烷基，被C 1-4烷氧基或CF 3取代的C 1-6烷氧基; R 3是氢，卤素或CF 3; R 4选自R 1的定义; R 5选自R 2的定义; R 6是含有2或3个氮原子的5元或6元杂环，其任选被= O，= S或C 1-4烷基取代，并且任选被氨基烷基取代; R 9a和R 9b是氢或C 1-4烷基，或R 9a和R 9b连接形成C5-7环; X是任选被氧代取代的C 1-4亚烷基; Y是任选被羟基取代的C 1-4烷基; 条件是如果Y是C 1-4烷基，则R 6至少被氨基烷基取代; 及其药学上可接受的盐和前药。 该化合物特别用于治疗疼痛，炎症，偏头痛和呕吐。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
    • 8. 发明申请
      WO2010007382A8 BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS 审中-公开
    • BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS
    • 苯并噻吩衍生物及其作为HSTAMINE H3拮抗剂的用途
    • WO2010007382A8
    • 2010-03-18
    • PCT/GB2009001774
    • 2009-07-17
    • TAKEDA PHARMACEUTICAL , POONI PARMINDER KAUR , MERCHANT KEVIN JOHN , KERR CATRINA , CROSBY STUART RICHARD , OKAWA TOMOHIRO , SASAKI MITSURU , GOTOU MIKA , SHOWELL GRAHAM ANDREW , TEALL MARTIN RICHARD
    • POONI PARMINDER KAUR , MERCHANT KEVIN JOHN , KERR CATRINA , CROSBY STUART RICHARD , OKAWA TOMOHIRO , SASAKI MITSURU , GOTOU MIKA , SHOWELL GRAHAM ANDREW , TEALL MARTIN RICHARD
    • C07D223/16 , A61K31/55 , A61P25/18 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
    • C07D403/12 , C07D223/16 , C07D401/06 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12
    • A compound having the formula (1) wherein: R1 is a group selected from C3-8 cycloalkyl, C1-6 alkyl, C1-6 alkylene-C3-8 cycloalkyl, each of which groups may optionally be substituted with C1-6 alkyl, halogen, haloC1-6 alkyl or OR15, or R1 is heterocyclyl, optionally substituted with C1-6 alkyl, haloC1-6 alkyl or OR15; n is 0, 1, 2, 3 or 4, the alkylene group -(CH2)n- formed thereby being optionally substituted with a group selected from C1-4 alkyl, C3-8 cycloalkyl and arylsulfonyl; A is a group selected from -N(R2)CO-, -CON(R2)-, -OC(O)-, -C(O)O-, -CO-, -C(R2)(OR3)-, -C(=N-O-R3)-, - C(=CR2R3)-, -C3-8 cycloalkylene-, -C(R2)(haloC1-6 alkyl)-, C1-4 alkylene and -C(OR3)(haloC1-6 alkyl)-; R2 and R3 are each independently selected from H, C1-6 alkyl, and C3-8 cycloalkyl, or, when A is -N(R2)CO- and X is absent, R2 may form, together with the adjacent nitrogen atom and Z, an N-containing heterocyclyl group, which may optionally be substituted; X is absent or is C1-4 alkylene or C2-4 alkenylene, each of which may optionally be substituted with one or more C1-4 alkyl groups, OR16, halogen or haloC1-6 alkyl; Z is selected from aryl, heteroaryl, C3-8 cycloalkyl, and heterocyclyl, each of which may optionally be substituted by a group selected from -Y-aryl, -Y-heteroaryl, -Y-C3-8 cycloalkyl and -Y-heterocyclyl, or, when X is present, Z may be H, or, when X is absent and A is -C(R2)(OR3)- or -N(R2)CO-, Z may be H, or, when A is -N(R2)CO- and X is absent, Z may form, together with the adjacent nitrogen atom and R2, an N-containing heterocyclyl group which may optionally be substituted, wherein, when A is -CO-, Z is linked to X or A via a carbon atom and wherein, when A is -N(R2)CO- and Z is H, R1 is C3-8 cycloalkyl; and Y represents a bond, C1-6 alkylene, CO, NR14, COC2-6 alkenylene, O, SO2 or NHCOC1-6 alkylene; wherein said cycloalkyl, aryl, heteroaryl and heterocyclyl groups Z may be optionally substituted by one or more substituents which may be the same or different, and which are selected from halogen, haloC1-6 alkyl, hydroxy, cyano, nitro, =O, -R4, -CO2R4, -COR4, -NR5R6, -C1-6 alkyl-NR5R6, -C3-8 cycloalkyl-NR5R6, - CONR12R13, -NR12COR13, -NR5SO2R6, -OCONR5R6, -NR5CO2R6, -NR4CONR5R6 or -SO2NR5R6- SHR8, -alkyl-OR8, -SOR8, -OR9, -SO2R9, -OSO2R9, -alkyl-SO2R9, -alkyl-CONHR9, -alkyl-SONHR9, -alkyl-COR10, -CO-alkyl-R10, -O-alkyl-R11 (wherein R4, R5 and R6 independently represent hydrogen, C1-6 alkyl, -C3-8 cycloalkyl, -C1-6 alkylene-C3-8 cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein R8 represents C1-6 alkyl, wherein R9 represents C1-6 alkyl or aryl, wherein R10 represents aryl, wherein R11 represents C3-8 cycloalkyl or aryl, R12, R13, R14, R15 and R16 each independently represent H or C1-6 alkyl, and wherein -NR5R6 and -NR12R13 may represent a nitrogen containing heterocyclyl group); wherein said R4, R5, R6 R8, R9, R11 and R11 groups may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C1-6 alkyl, C1-6 alkoxy, cyano, amino, =O or trifluoromethyl; and wherein substituents of Z selected from -Y-aryl, -Y-heteroaryl, -Y-C3-8cycloalkyl and -Y-heterocyclyl may be optionally substituted by one or more substituents selected from =O, hydroxy, cyano, nitro, halogen, haloC1-6 alkyl and C1-6alkyl; and wherein, when A is C1-4 alkylene, said cycloalkyl, aryl, heteroaryl or heterocyclyl group Z (such as a heterocyclyl group Z) is substituted at least with hydroxy, CF3, or =0; and wherein, when A is CON(R2) n is 1; or a pharmaceutically acceptable salt or ester thereof, provided that: when A is -CO-, R1 is CH3, C3-8 cycloalkyl-substituted C1-6 alkylene or n-butyl, n is 0 and X is -CH2CH2-, Z is not N-benzyl substituted 4-piperidinyl, N-(3-fluorobenzyl)-substituted 4-piperidinyl or N-acetyl substituted 4-piperidinyl; when A is -OC(O)-, R1 is cyclobutyl, n is 0 and X is -CH2CH2-, Z is not H; when A is -OC(O)-, R1 is n-propyl, n is 0 and X is -CH2-, Z is not H; and when A is -CO-, R1 is CH3, n is 0 and X is CH2, Z is not H.
    • 具有式（1）的化合物，其中：R 1是选自C 3-8环烷基，C 1-6烷基，C 1-6亚烷基-C 3-8环烷基，其各自可以任选被C 1-6烷基取代， 卤素，卤代C 1-6烷基或OR 15，或R 1是任选被C 1-6烷基，卤代C 1-6烷基或OR 15取代的杂环基; n为0,1,2,3或4，由此形成的亚烷基 - （CH 2）n任选被选自C 1-4烷基，C 3-8环烷基和芳基磺酰基的基团取代; A是选自-N（R2）CO-，-CON（R2） - ，-OC（O） - ， - （O）O-，-CO-，-C（R2）（OR3） -C（= NO-R 3） - ， - C（= CR 2 R 3） - ， - C 3-8亚环烷基 - ， - C（R 2）（卤代C 1-6烷基） - ，C 1-4亚烷基和-C（OR 3） -6烷基） - ; R2和R3各自独立地选自H，C1-6烷基和C3-8环烷基，或当A是-N（R2）CO-且X不存在时，R2可以与相邻的氮原子和Z ，可以任选被取代的含N的杂环基; X不存在或是C 1-4亚烷基或C 2-4亚烯基，其各自可以任选被一个或多个C 1-4烷基，OR 16，卤素或卤代C 1-6烷基取代; Z选自芳基，杂芳基，C 3-8环烷基和杂环基，其各自可任选被选自-Y-芳基，-Y-杂芳基，-Y-C 3-8环烷基和-Y-杂环基 或当X存在时，Z可以是H，或者当X不存在且A是-C（R 2）（OR 3） - 或-N（R 2）CO-时，Z可以是H，或者当A是 -N（R2）CO-和X不存在，Z可以与相邻的氮原子一起形成，R 2可以任选被取代的含N的杂环基，其中当A是-CO-时，Z连接到 X或A通过碳原子，并且其中当A是-N（R 2）CO-且Z是H时，R 1是C 3-8环烷基; Y表示键，C 1-6亚烷基，CO，NR 14，COC 2-6亚烯基，O，SO 2或NHCOC 1-6亚烷基; 其中所述环烷基，芳基，杂芳基和杂环基基团Z可以任选地被一个或多个可以相同或不同的取代基取代，并且选自卤素，卤代C 1-6烷基，羟基，氰基，硝基，= O - R4，-CO 2 R 4，-COR 4，-NR 5 R 6，-C 1-6烷基-NR 5 R 6，-C 3-8环烷基-NR 5 R 6，-CONR 12 R 13，-NR 12 COR 13，-NR 5 SO 2 R 6，-OCONR 5 R 6，-NR 5 CO 2 R 6，-NR 4 CONR 5 R 6或-SO 2 NR 5 R 6 -SHR 8， - 烷基-OR 8，-SOR 8，-OR 9，-SO 2 R 9，-OSO 2 R 9， - 烷基-SO 2 R 9 - - 烷基-CONHR 9 - - 烷基-SHHR 9， - 烷基-CON10，-CO-烷基-R10，-O-烷基-R11 （其中R 4，R 5和R 6独立地表示氢，C 1-6烷基，-C 3-8环烷基，-C 1-6亚烷基-C 3-8环烷基，芳基，杂环基或杂芳基，其中R 8表示C 1-6烷基， C 1-6烷基或芳基，其中R 10表示芳基，其中R 11表示C 3-8环烷基或芳基，R 12，R 13，R 14，R 15和R 16各自独立地表示H或C 1-6烷基，并且其中-NR 5 R 6和-NR 12 R 13可以表示 含氮杂环基）; 其中所述R 4，R 5，R 6，R 8，R 9，R 11和R 11基团可以任选地被一个或多个可以相同或不同的取代基取代，并且选自卤素，羟基，C 1-6烷基， C 1-6烷氧基，氰基，氨基，= O或三氟甲基; 并且其中选自-Y-芳基，-Y-杂芳基，-Y-C3-8环烷基和-Y-杂环基的Z的取代基可以任选地被一个或多个选自以下的取代基取代：选自= O，羟基，氰基，硝基，卤素， 卤代C 1-6烷基和C 1-6烷基; 并且其中当A为C 1-4亚烷基时，所述环烷基，芳基，杂芳基或杂环基Z（例如杂环基Z）至少被羟基，CF 3或= 0取代; 并且其中当A是CON（R2）时，n是1; 或其药学上可接受的盐或酯，条件是：当A为-CO-时，R 1为CH 3，C 3-8环烷基取代的C 1-6亚烷基或正丁基，n为0且X为-CH 2 CH 2 - ，Z为 不是N-苄基取代的4-哌啶基，N-（3-氟苄基）取代的4-哌啶基或N-乙酰基取代的4-哌啶基; 当A为-OC（O） - 时，R1为环丁基，n为0，X为-CH2CH2-，Z为H; 当A为-OC（O） - 时，R 1为正丙基，n为0且X为-CH 2 - ，Z不为H; 当A为-CO-时，R 1为CH 3，n为0，X为CH 2，Z为H。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
    • 10. 发明申请
      WO1997018206A1 MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS 审中-公开
    • MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS
    • 吗啉衍生物及其用作治疗药物
    • WO1997018206A1
    • 1997-05-22
    • PCT/GB1996002766
    • 1996-11-13
    • MERCK SHARP & DOHME LIMITED , SWAIN, Christopher, John , TEALL, Martin, Richard , WILLIAMS, Brian, John
    • MERCK SHARP & DOHME LIMITED
    • C07D413/04
    • C07D413/04 , C07D417/04
    • The present invention relates to compounds of formula (I) wherein X is a 5- or 6-membered C-linked heteroaromatic ring containing 1 to 4 nitrogen atoms and optionally containing in the ring one oxygen or sulphur atom; Y is a group of the formula -(CH2)nNR R , or a methylene- or ethylene-linked imidazolyl group; Z is hydrogen or C1-4alkyl optionally substituted by a hydroxy group; R , R , R , R , R , R and R are a variety of substituents; R is hydrogen, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, phenyl, or C2-4alkyl substituted by C1-4alkoxy or hydroxy; R is hydrogen, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-4alkyl, phenyl, or C2-4alkyl substituted by one or two substituents selected from C1-4alkoxy, hydroxy or a 4-, 5- or 6-membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S; or R and R , together with the nitrogen atom to which they are attached, form a saturated or partially saturated heterocyclic ring or a non-aromatic azabicyclic ring system; and n is zero, 1 or 2; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherapeutic neuralgia.
    • 本发明涉及式（I）化合物，其中X是含有1至4个氮原子并且任选地在环中含有一个氧或硫原子的5-或6-元C-连接的杂芳环; Y是式 - （CH 2）n NR 6 R 7或亚甲基或亚乙基连接的咪唑基的基团; Z是氢或任选被羟基取代的C 1-4烷基; R 1，R 2，R 3，R 4，R 5，R 9a和R 9b是各种取代基; R 6是氢，C 1-6烷基，C 3-7环烷基，C 3-7环烷基C 1-4烷基，苯基或被C 1-4烷氧基或羟基取代的C 2-4烷基; R 7是氢，C 1-6烷基，C 3-7环烷基，C 3-7环烷基C 1-4烷基，苯基或被一个或两个选自C 1-4烷氧基，羟基或4-，5-或6-烷氧基的取代基取代的C 2-4烷基， 含有一个或两个选自N，O和S的杂原子的6-元杂脂族环; 或R 6和R 7与它们所连接的氮原子一起形成饱和或部分饱和的杂环或非芳族氮杂双环体系; n为零，1或2; 或其药学上可接受的盐。 该化合物特别用于治疗或预防疼痛，炎症，偏头痛，呕吐和治疗后神经痛。
    • 基本信息 添加关注 加入工作空间 PDF全文 PDF下载 全文下载 相似专利 双屏查看 权利要求书 说明书全文 Global Dossier Espacenet 法律信息 同族专利 专利引用
每页展示10个专利
每页展示10个专利
每页展示20个专利
每页展示50个专利
每页展示100个专利

IPRDB

最新中国发明专利 最新美国发明专利 技术领域 专利库 专利分类库 国际专利分类库

热门服务

会员版试用 API 数据接口 找代理 知嘟嘟专利交易 排行榜 大学排行榜 专利百科

关于我们

平台介绍 战略合作 网站地图

友情链接

知嘟嘟专利交易 国家知识产权局 中国商标网

联系方式


©2019-2023 上海吉码数字技术有限公司 版权所有，并保留所有权利 沪ICP备20016256号-6 沪公网安备31011702005475号